This article first appeared on GuruFocus .
Release Date: November 05, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
SINTX Technologies Inc ( NASDAQ:SINT ) achieved record quarterly revenue of approximately $2.2 million, a 953% year-over-year increase, driven by industrial and aerospace ceramics manufacturing.
-
Gross profit surged to approximately $1.4 million with gross margins improving to 62% from 45% in the prior year period, reflecting pricing adjustments, favorable product mix, and improved manufacturing efficiencies.
-
Net loss narrowed by 55% year-over-year to $1.6 million, demonstrating progress toward financial sustainability through improved gross profitability and disciplined expense management.
-
SINTX Technologies Inc ( NASDAQ:SINT ) successfully executed a warrant call generating approximately $2 million in gross proceeds, while unexercised warrants covering 941,000 shares expired, reducing potential dilution for existing shareholders.
-
The company manufactured and delivered more silicon nitride parts than in any other quarter in its history, demonstrating its capacity to manufacture at scale and exceeding the high end of its revenue guidance by two times.
Negative Points
-
SINTX Technologies Inc ( NASDAQ:SINT ) continues to incur operating losses and use cash in operations, with net cash used in operating activities of $6.6 million for the first nine months of 2026.
-
Cash and cash equivalents decreased to $2 million at September 30, 2026, from $4.1 million at December 31, 2025, raising concerns about liquidity and the need for additional capital.
-
The company is unable to provide revenue guidance for the fourth quarter of 2026 regarding the timing and delivery of the remaining $3.2 million in purchase orders received in June, creating uncertainty about future revenue.
-
Quarterly revenue may fluctuate significantly based on the timing and size of customer orders, production schedules, and shipment timing, making it difficult to treat a single strong quarter as a guaranteed future run rate.
-
SINTX Technologies Inc ( NASDAQ:SINT ) remains dependent on raising additional capital through equity and debt financing to support ongoing operations and commercialization initiatives, which could lead to further dilution for shareholders.
Q & A Highlights
Q: What drove the 953% year-over-year revenue growth in Q3 2026, and what does it signal about SINTX's commercial transition? A: CEO Eric Olson said Q3 revenue reached approximately $2.2 million versus $208,000 a year earlier, driven primarily by industrial and aerospace ceramics manufacturing. He noted SINTX manufactured and delivered more silicon nitride parts than in any other quarter in company history, demonstrating commercial scale and operational efficiency. Gross profit was approximately $1.4 million, and net loss narrowed 55% year-over-year.
Q: How did gross margin improve so significantly in the quarter? A: CFO Kevin Trask said gross margin rose to 62% from 45% in Q3 2025, driven by pricing adjustments implemented earlier this year, favorable product mix, and increased production volumes that improved manufacturing efficiencies and better absorbed fixed manufacturing costs.
Q: What is the status of the warrant call and its impact on dilution? A: CEO Eric Olson said achieving the Q3 revenue milestone allowed SINTX to execute a warrant call, generating approximately $2 million in gross capital proceeds. The remaining unexercised Class B warrants covering about 941,000 shares expired without consideration, reducing potential dilution to existing shareholders.
Q: What is the outlook for Q4 2026 revenue given the prior guidance? A: CFO Kevin Trask said the previously communicated Q4 2026 guidance was based on expected delivery timing against $3.2 million in purchase orders received in June. However, due to timing and delivery variability, the company is currently unable to offer an expectation for delivery of the remainder of those orders relative to Q4 2026, and expects to provide greater visibility as information becomes available.
Q: How is the commercialization of the Synergy foot and ankle wedge system progressing? A: CEO Eric Olson said full commercialization has begun following completion of the limited-use release, with distributors targeting leading foot and ankle surgeons in the U.S. The company is also exploring strategic partnerships with parties that have existing relationships with facilities and surgeons. Success will be measured through surgeon adoption, product availability, repeat procedures, and meaningful revenue.
Q: What is the latest on the 3D-printed silicon nitride PEEK biocomposite platform? A: CEO Eric Olson said SINTX's manufacturing and innovation teams have created a new 3D printing manufacturing facility and begun developing custom workflows for 3D-printed implant applications. Under a manufacturing agreement, Evonik produces commercial-scale PEEK/silicon nitride composite filament using SINTX's patent and material. The company anticipates greater manufacturing yields, lower cost of goods, and less waste versus other processes.
Q: What is the timeline and purpose of the medical textiles animal studies? A: CEO Eric Olson said SINTX is conducting large animal in vivo studies to evaluate silicon nitride-treated medical textiles, including antimicrobial and anti-adhesion scar reduction properties of treated sutures and wound dressings. The studies are expected to be completed in the next calendar quarter and will inform future development and potential commercial partnering, with a long-term vision of a licensing platform.
Q: What is the current liquidity position and capital-raising strategy? A: CFO Kevin Trask said cash and cash equivalents were $2 million at September 30, 2026, versus $4.1 million at year-end 2025. Net cash used in operations was $6.6 million for the first nine months of 2026. The company had approximately $5 million of remaining capacity under its at-the-market offering and continues to evaluate additional equity and debt financing to support operations and commercialization.
Q: Why did reported R&D expenses decline, and does it reflect reduced research effort? A: CFO Kevin Trask said R&D expenses were $548,000 versus $1.3 million in the prior-year period, primarily reflecting reallocation of certain overhead costs from R&D to G&A as operations shifted toward commercial manufacturing. He emphasized these changes do not represent a corresponding reduction in underlying research and development efforts.
Q: What are SINTX's key priorities for the remainder of 2026 and into 2027? A: CEO Eric Olson outlined four priorities: reliable manufacturing and commercial execution of industrial and aerospace products; commercialization of the Synaptic foot and ankle implant system; advancement of silicon nitride composites for 3D manufacturing; and identifying licensing opportunities for silicon nitride textiles with strategic partners, alongside disciplined management of costs and working capital.
Q: How should investors interpret the strong Q3 revenue relative to future quarters? A: CFO Kevin Trask cautioned that quarterly revenue may fluctuate based on timing and size of customer orders, production schedules, and shipment timing. He said the company remains focused on sustainable gross profit generation and converting demand into cash rather than treating a single strong quarter as a guaranteed future run rate, though it expects technical manufacturing demand to remain above historical levels.
Q: What is the significance of SINTX's manufacturing facility to its strategy? A: CEO Eric Olson said SINTX operates a one-of-a-kind vertically integrated manufacturing facilitythe only facility registered with the FDA to manufacture medical-grade silicon nitride biomaterials. Combined with recent patents for integrating silicon nitride into composites and textiles, this capability allows the platform to move beyond traditional orthopedic devices into other biotech applications.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
